Enanta Pharmaceuticals Inc (ENTA)
12.12
-0.94
(-7.20%)
USD |
NASDAQ |
May 17, 16:00
12.12
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals Enterprise Value: -43.40M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -43.40M |
| May 16, 2024 | -23.71M |
| May 15, 2024 | -17.78M |
| May 14, 2024 | -19.89M |
| May 13, 2024 | -26.88M |
| May 10, 2024 | -32.39M |
| May 09, 2024 | -26.46M |
| May 08, 2024 | -30.06M |
| May 07, 2024 | -22.86M |
| May 06, 2024 | 8.909M |
| May 03, 2024 | 20.98M |
| May 02, 2024 | -5.704M |
| May 01, 2024 | -13.12M |
| April 30, 2024 | -9.305M |
| April 29, 2024 | -19.69M |
| April 26, 2024 | -38.33M |
| April 25, 2024 | -36.00M |
| April 24, 2024 | -26.68M |
| April 23, 2024 | -21.81M |
| April 22, 2024 | -15.66M |
| April 19, 2024 | -18.21M |
| April 18, 2024 | -20.11M |
| April 17, 2024 | -3.804M |
| April 16, 2024 | 25.00M |
| April 15, 2024 | 41.73M |
| Date | Value |
|---|---|
| April 12, 2024 | 48.08M |
| April 11, 2024 | 54.44M |
| April 10, 2024 | 49.99M |
| April 09, 2024 | 55.92M |
| April 08, 2024 | 46.18M |
| April 05, 2024 | 49.36M |
| April 04, 2024 | 42.37M |
| April 03, 2024 | 53.59M |
| April 02, 2024 | 45.97M |
| April 01, 2024 | 60.16M |
| March 31, 2024 | 69.48M |
| March 28, 2024 | 32.23M |
| March 27, 2024 | 12.56M |
| March 26, 2024 | 0.2872M |
| March 25, 2024 | -42.24M |
| March 22, 2024 | -28.48M |
| March 21, 2024 | -27.64M |
| March 20, 2024 | -30.39M |
| March 19, 2024 | -40.12M |
| March 18, 2024 | -51.33M |
| March 15, 2024 | -36.52M |
| March 14, 2024 | -43.93M |
| March 13, 2024 | -31.66M |
| March 12, 2024 | -29.54M |
| March 11, 2024 | -18.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-197.65M
Minimum
Nov 13 2023
1.735B
Maximum
Nov 05 2021
644.83M
Average
659.80M
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.747B |
| Galectin Therapeutics Inc | 261.87M |
| Viking Therapeutics Inc | 6.425B |
| Akero Therapeutics Inc | 508.63M |
| 89bio Inc | 311.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.16M |
| Revenue (Quarterly) | 17.05M |
| Total Expenses (Quarterly) | 49.82M |
| EPS Diluted (Quarterly) | -1.47 |
| Profit Margin (Quarterly) | -182.7% |
| Earnings Yield | -51.44% |
| Normalized Earnings Yield | -51.44 |